Biotie stock dips as UCB drops tozadenant in Parkinson’s disease
By Cormac Sheridan
Friday, March 21, 2014
Shares in Biotie Therapies Oyj dipped 7 percent Friday as partner UCB SA opted not to pursue phase III development of the Parkinson’s disease drug tozadenant, a selective inhibitor of the adenosine 2a (A2A) receptor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.